Evidence map›Paper›PMID 40541941›Full record

ArticleNPJ Parkinson's disease2025

Dopamine and cortical neurons with different Parkinsonian mutations show variation in lysosomal and mitochondrial dysfunction.

Jessica Chedid, Yan Li, Adahir Labrador-Garrido, Dad Abu-Bonsrah, Chiara Pavan, Tyra Fraser, Dmitry Ovchinnikov, Melanie Zhong, Ryan Davis, Dario Strbenac and 8 more

Abstract read
In one paragraph

Article in NPJ Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Jessica ChedidThe University of Sydney, Brain and Mind Centre & Faculty of Medicine and Health School of Medical Sciences, Sydney, NSW, Australia.
Yan LiAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.
Adahir Labrador-GarridoThe University of Sydney, Brain and Mind Centre & Faculty of Medicine and Health School of Medical Sciences, Sydney, NSW, Australia.
Dad Abu-BonsrahAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.
Chiara PavanAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.
Tyra FraserAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.
Dmitry OvchinnikovAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.
Melanie ZhongThe University of Sydney, Brain and Mind Centre & Faculty of Medicine and Health School of Medical Sciences, Sydney, NSW, Australia.
Ryan DavisAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.
Dario StrbenacAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.
Jennifer A JohnstonAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.
Lachlan H ThompsonAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.
Deniz KirikAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.
Clare L ParishAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.
Glenda M HallidayThe University of Sydney, Brain and Mind Centre & Faculty of Medicine and Health School of Medical Sciences, Sydney, NSW, Australia.
Carolyn M SueAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.
Gautam WaliAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA. g.wali@unsw.edu.au.
Nicolas DzamkoThe University of Sydney, Brain and Mind Centre & Faculty of Medicine and Health School of Medical Sciences, Sydney, NSW, Australia. nicolas.dzamko@sydney.edu.au.

Funding

Aligning Science Across Parkinson's ASAP-000497
6 · The paper itself

Abstract

Mutations causing Parkinson's disease (PD) give diverse pathological phenotypes whose cellular correlates remain to be determined. Those with PRKN mutations have significantly earlier selective vulnerability of dopamine neurons, those with SNCA mutations have increased alpha-synuclein deposition, while those with LRRK2 mutations have additional deposition of tau. Yet all three mutation types are implicated in mitochondrial and/or lysosomal dysfunction. To compare cellular dysfunctions associated with these different pathological phenotypes, an unbiased high-content imaging platform was developed to assess both lysosomal and mitochondrial dysfunction, along with alpha-synuclein and tau protein deposition using induced pluripotent stem cell (iPSC) derived cortical and ventral midbrain neurons. Different PD mutations caused cell type specific dysfunctions, likely to impact on both selective neuronal vulnerability and the pathologies observed in PD. Comparison of dopamine neurons identified that both lysosomal and mitochondrial dysfunction were predominant with PRKN lof mutations, whereas SNCA A53T and LRRK2 R1441G mutations had increased tau deposition. In contrast, cortical neurons with SNCA and LRRK2 mutations both had mitochondrial and autophagy impairments without protein deposition, with LRRK2 cells additionally showing decreased glucocerebrosidase activity and increased alpha-synuclein phosphorylation.

Identifiers

PMID40541941
PMCPMC12181412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.